Guselkumab in East Asians With Moderate-to-Severe Ulcerative Colitis: Subgroup Analysis of the QUASAR Induction and Maintenance Studies.
J Gastroenterol Hepatol · 2025-Sep · PMID 40574492
Symptomatic Remission
FIGURE 3 Summary of primary and major secondary efficacy outcomes in the Phase 2b and Phase 3 QUASAR induction studies (East Asian subpopulation versus global population). Footnote: AE, adverse event; GUS, guselkumab; I‐0, induction Week 0; I‐12, induction Week 12; IBDQ, Inflammatory Bowel Disease Questionnaire; IV, intravenous; PRO, patient‐reported outcome; PROMIS, Patient‐Reported Outcomes Measurement Information System; pts, participants. Includes only participants with modified Mayo score 5–9 at induction baseline. Data for global participants have been reported previously [23, 24]. Clinical response is defined as a decrease from induction baseline in the modified Mayo score by ≥ 30% and ≥ 2 points, with either a ≥ 1‐point decrease from baseline in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1. Clinical remission is defined as a stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1 with no friability present on the endoscopy. Histologic‐endoscopic mucosal improvement is defined as achieving a combination of histologic improvement and endoscopic improvement. Histologic improvement is defined as neutrophil infiltration in < 5% of crypts, no crypt destruction, and no erosions, ulcerations, or granulation tissue according to the Geboes grading system. Endoscopic remission (normalization) is defined as an endoscopy subscore of 0. Histologic remission is defined as absence of neutrophils from the mucosa (both lamina propria and epithelium), no crypt destruction, and no erosions, ulcerations or granulation tissue according to the Geboes grading system. Symptomatic remission is defined as a stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0, where the stool frequency subscore has not increased from induction baseline. IBDQ remission is defined as a total IBDQ score ≥ 170. Fatigue response is defined as ≥ 7‐point improvement from induction baseline in the PROMIS‐Fatigue Short Form 7a.
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | quality_warning | 待验证 | 1 | 2026-07-23T18:02:04+00:00 |